Rabi Sankar Bhatta

Rabi Sankar Bhatta

Auto-generated profile, based on publicly available information

Rabi Sankar Bhatta

Pharmaceutics & Pharmacokinetics Division CSIR‐Central Drug Research Institute Lucknow Uttar Pradesh India

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2024 in ACS Infectious Diseases
Verified
Journal Article
Closed access
ABAmol Chhatrapati Bisen
Amol Chhatrapati Bisen
SSSachin Nashik Sanap
Sachin Nashik Sanap
SASristi Agrawal
Sristi Agrawal
ABArpon Biswas
Arpon Biswas
AMAnjali Mishra
Anjali Mishra
RBRabi Sankar Bhatta
Rabi Sankar Bhatta

1 September 2015 in Journal of Chromatography B
Verified
Journal Article
Closed access
MBManisha Bhateria
Manisha Bhateria
RRRamakrishna Rachumallu
Ramakrishna Rachumallu
DPDora Babu Pakala
Dora Babu Pakala
RBRabi Sankar Bhatta
Rabi Sankar Bhatta

21 January 2014 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
RSRAJBIR SINGH
RAJBIR SINGH
RRRamakrishna Rachumallu
Ramakrishna Rachumallu
MBManisha Bhateria
Manisha Bhateria
RBRabi Sankar Bhatta
Rabi Sankar Bhatta

1 February 2024 in Journal of Ocular Pharmacology and Therapeutics
Verified
Journal Article
Closed access
ABArpon Biswas
Arpon Biswas
ACAbhijit Deb Choudhury
Abhijit Deb Choudhury
SASristi Agrawal
Sristi Agrawal
ABAmol Chhatrapati Bisen
Amol Chhatrapati Bisen
SSSachin Nashik Sanap
Sachin Nashik Sanap
RBRabi Sankar Bhatta
Rabi Sankar Bhatta
Purpose: Diabetic retinopathy (DR) is a microvascular retinal disease associated with chronic diabetes mellitus, characterized by the damage of blood vessels in the eye. It is projected to become the leading cause of blindness, given the increasing burden of the diabetic population worldwide. The diagnosis and management of DR pose significant challenges for physicians because of the involvement of multiple biochemical pathways and the complexity of ocular tissues. This review aims to provide a comprehensive understanding of the molecular pathways implicated in the pathogenesis of DR, including the polyo pathway, hexosamine pathway, protein kinase C (PKC), JAK/STAT signaling pathways, and the renin–angiotensin system (RAS). Methods: Academic databases such as PubMed, Scopus, Google Scholar and Web of Science was systematically searched using a carefully constructed search strategy incorporating keywords like “Diabetic Retinopathy,” “Molecular Pathways,” “Pharmacological Treatments,” and “Clinical Trials” to identify relevant literature for the comprehensive review. Results: In addition to activating other inflammatory cascades, these pathways contribute to the generation of oxidative stress within the retina. Furthermore, it aims to explore the existing pharmacotherapy options available for the treatment of DR. In addition to conventional pharmacological therapies such as corticosteroids, antivascular endothelial growth factors, and nonsteroidal anti-inflammatory drugs (NSAIDs), this review highlights the potential of repurposed drugs, phyto-pharmaceuticals, and novel pipeline drugs currently undergoing various stages of clinical trials. Conclusion: Overall, this review serves as a technical exploration of the complex nature of DR, highlighting both established and emerging molecular pathways implicated in its pathogenesis. Furthermore, it delves into the available pharmacological treatments, as well as the promising repurposed drugs, phyto-pharmaceuticals, and novel drugs currently being evaluated in clinical trials, with a focus on their specific mechanisms of action.

31 May 2014 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
MBManisha Bhateria
Manisha Bhateria
RRRamakrishna Rachumallu
Ramakrishna Rachumallu
RSRAJBIR SINGH
RAJBIR SINGH
RBRabi Sankar Bhatta
Rabi Sankar Bhatta
Erythrocytes (red blood cells [RBCs]) and artificial or synthetic delivery systems such as liposomes, nanoparticles (NPs) are the most investigated carrier systems. Herein, progress made from conventional approach of using RBC as delivery systems to novel approach of using synthetic delivery systems based on RBC properties will be reviewed. We aim to highlight both conventional and novel approaches of using RBCs as potential carrier system. Conventional approaches which include two main strategies are: i) directly loading therapeutic moieties in RBCs; and ii) coupling them with RBCs whereas novel approaches exploit structural, mechanical and biological properties of RBCs to design synthetic delivery systems through various engineering strategies. Initial attempts included coupling of antibodies to liposomes to specifically target RBCs. Knowledge obtained from several studies led to the development of RBC membrane derived liposomes (nanoerythrosomes), inspiring future application of RBC or its structural features in other attractive delivery systems (hydrogels, filomicelles, microcapsules, micro- and NPs) for even greater potential. In conclusion, this review dwells upon comparative analysis of various conventional and novel engineering strategies in developing RBC based drug delivery systems, diversifying their applications in arena of drug delivery. Regardless of the challenges in front of us, RBC based delivery systems offer an exciting approach of exploiting biological entities in a multitude of medical applications.

11 October 2022 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
SSSachin Nashik Sanap
Sachin Nashik Sanap
ABAmol Chhatrapati Bisen
Amol Chhatrapati Bisen
AKAshwini Kedar
Ashwini Kedar
KYKaran Singh Yadav
Karan Singh Yadav
AKAtul Krishna
Atul Krishna
RBRabi Sankar Bhatta
Rabi Sankar Bhatta